

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT3127925

SUBMISSION TYPE:	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:	MERGER	
EFFECTIVE DATE:	12/24/2005	
CONVEYING PARTY DATA		
	Name	Execution Date
	AMBION, INC.	12/24/2005
RECEIVING PARTY DATA		
Name:	APPLERA CORPORATION	
Street Address:	850 LINCOLN CENTRE DRIVE	
City:	FOSTER CITY	
State/Country:	CALIFORNIA	
Postal Code:	94404	
PROPERTY NUMBERS Total: 1		
	Property Type	Number
	Application Number:	14542841
CORRESPONDENCE DATA		
Fax Number:		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
Email:	LifetechDocket@system.foundationip.com	
Correspondent Name:	MICHAEL SMITH	
Address Line 1:	5791 VAN ALLEN WAY	
Address Line 2:	LIFE TECHNOLOGIES CORPORATION	
Address Line 4:	CARLSBAD, CALIFORNIA 92008	
ATTORNEY DOCKET NUMBER:	6557 C4 US	
NAME OF SUBMITTER:	ELIZABETH MORGAN	
SIGNATURE:	/Elizabeth Morgan/	
DATE SIGNED:	12/02/2014	
Total Attachments: 18		
source=6557C4US_Merger_Ambion-Applera#page1.tif		
source=6557C4US_Merger_Ambion-Applera#page2.tif		
source=6557C4US_Merger_Ambion-Applera#page3.tif		
source=6557C4US_Merger_Ambion-Applera#page4.tif		
source=6557C4US_Merger_Ambion-Applera#page5.tif		
source=6557C4US_Merger_Ambion-Applera#page6.tif		

PATENT

source=6557C4US_Merger_Ambion-Applera#page7.tif
source=6557C4US_Merger_Ambion-Applera#page8.tif
source=6557C4US_Merger_Ambion-Applera#page9.tif
source=6557C4US_Merger_Ambion-Applera#page10.tif
source=6557C4US_Merger_Ambion-Applera#page11.tif
source=6557C4US_Merger_Ambion-Applera#page12.tif
source=6557C4US_Merger_Ambion-Applera#page13.tif
source=6557C4US_Merger_Ambion-Applera#page14.tif
source=6557C4US_Merger_Ambion-Applera#page15.tif
source=6557C4US_Merger_Ambion-Applera#page16.tif
source=6557C4US_Merger_Ambion-Applera#page17.tif
source=6557C4US_Merger_Ambion-Applera#page18.tif

AGREEMENT AND PLAN OF MERGER

THIS AGREEMENT AND PLAN OF MERGER (this "*Agreement*"), dated as of December 24, 2005, is made by and among Ambion, Inc., a Delaware corporation (the "*Company*"), Applera Corporation, a Delaware corporation ("*Parent*"), Ambion Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent ("*Merger Subsidiary*"), and Matthew M. Winkler, in his capacity as Representative (as hereinafter defined).

RECITALS

WHEREAS, the Boards of Directors of the Company, Parent and Merger Subsidiary deem it advisable and in the best interest of their respective Stockholders to consummate the transactions contemplated by this Agreement on the terms and subject to the conditions provided for herein;

WHEREAS, in furtherance thereof it is proposed that the acquisition be accomplished by the merger of Merger Subsidiary with and into the Company, with the Company being the surviving corporation, in accordance with the General Corporation Law of the State of Delaware (the "*DGCL*");

WHEREAS, the Boards of Directors of the Company, Parent (on its own behalf and as sole stockholder of Merger Subsidiary) and Merger Subsidiary have each approved this Agreement, the Merger (as hereinafter defined) and the other transactions contemplated hereby;

WHEREAS, simultaneously with the execution and delivery of this Agreement, the Company and Asuragen, Inc., a Delaware corporation ("*Asuragen*"), are entering into (i) an Asset Purchase Agreement in the form of Exhibit A hereto (including all schedules and exhibits attached thereto, the "*Asset Purchase Agreement*"), pursuant to which the Surviving Corporation will sell, transfer and assign to Asuragen and Asuragen will purchase and assume from the Surviving Corporation certain assets and liabilities relating to the Diagnostics Business, following the Closing, (ii) one or more licensing agreements pursuant to which the Surviving Corporation and Asuragen will license to one another the right to use certain intellectual property, (iii) a transition services agreement whereby the Surviving Corporation will provide certain IT, accounting and other services to Asuragen for a specified period of time after Closing, and (iv) such other strategic arrangements mutually agreed to between the Surviving Corporation and Asuragen (the matters set forth in clauses (i) through (iv) being referred to herein collectively as the "*Divestiture*");

WHEREAS, simultaneously with the execution and delivery of this Agreement, and as a condition and inducement to Parent to enter into this Agreement, the employee of the Company identified on Exhibit B (the "*Key Employee*") is executing an Employment and Noncompetition Agreement in the form of Exhibit C (the "*Employment and Noncompetition Agreement*") to be effective upon the Closing; and

WHEREAS, the Company, Parent and Merger Subsidiary desire to make certain representations, warranties, covenants and agreements in connection with the Merger and also to prescribe various conditions to the Merger.

ARTICLE II THE MERGER

2.1 **Merger.** Upon the terms and subject to the conditions set forth in this Agreement, at the Effective Time, Merger Subsidiary shall be merged with and into the Company (the "*Merger*") in accordance with the terms of, and subject to the conditions set forth in, this Agreement and the DGCL. Following the Merger, the Company shall continue as the surviving corporation in the Merger (sometimes hereinafter referred to as the "*Surviving Corporation*") and the separate corporate existence of Merger Subsidiary shall cease.

2.2 **Effective Time.** As a part of the Closing, the Company, Parent and Merger Subsidiary shall cause a Certificate of Merger meeting the requirements of Section 251 of the DGCL (the "*Certificate of Merger*") to be properly executed and filed with the Secretary of State of the State of Delaware in accordance with the terms and conditions of the DGCL. The Merger shall become effective 11:59 p.m. Eastern Time on the date the Certificate of Merger is filed with the Secretary of State of the State of Delaware in accordance with the DGCL (the "*Effective Time*").

2.3 **Effects of the Merger.** At and after the Effective Time, the Merger shall have the effects set forth in the DGCL. Without limiting the generality of the foregoing and subject thereto, at the Effective Time all the property, rights, privileges, immunities, powers and franchises of the Company and Merger Subsidiary shall vest in the Surviving Corporation, and all Debts, liabilities, obligations and duties of the Company and Merger Subsidiary shall become the debts, liabilities, obligations and duties of the Surviving Corporation.

2.4 **Certificate of Incorporation and Bylaws.** The certificate of incorporation and bylaws of the Company in effect immediately prior to the Effective Time shall be the certificate of incorporation and bylaws of the Surviving Corporation as of the Effective Time, until duly amended in accordance with Applicable Laws.

2.5 **Directors and Officers.** The directors and officers of Merger Subsidiary immediately prior to the Effective Time shall be the directors and officers of the Surviving Corporation as of the Effective Time.

2.6 **Conversion of Outstanding Shares.** At the Effective Time, by virtue of the Merger and without any action on the part of any party:

(a) Each share of common stock, par value \$.01 per share, of Merger Subsidiary issued and outstanding immediately prior to the Effective Time shall remain outstanding and shall represent one share of common stock, par value \$.01 per share, of the Surviving Corporation, so that, after the Effective Time, Parent shall be the holder of all of the issued and outstanding shares of the Surviving Corporation's common stock.

(b) Each share of Common Stock (other than Dissenting Shares) outstanding immediately prior to the Effective Time (each, an "*Outstanding Common Share*" and collectively, the "*Outstanding Common Shares*"), (i) shall be converted into the right to

(iii) Neither the Company nor any member of its Aggregated Group has any obligations to provide post-termination health or welfare benefits (other than in accordance with COBRA), nor has any formal plan or commitment (whether legally binding or not) either to create any plan or arrangement that would constitute an Employee Benefit Plan, or to make any contributions, modifications, or changes to any Employee Benefit Plan outside the ordinary course of business and inconsistent with past practice with regard to amounts.

(iv) In the past two years, (i) none of the Company or any member of the Aggregated Group has effectuated a "plant closing" (as defined in the WARN Act) affecting any site of employment or one or more facilities or operating units within any site of employment or facility of its business, (ii) there has not occurred a "mass layoff" (as defined in the WARN Act) affecting any site of employment or facility of the business of the Company or any member of its Aggregated Group, and (iii) none of the Company or any member of its Aggregated Group has been affected by any transaction or engaged in layoffs or employment terminations sufficient in number to trigger application of any similar state, local or foreign law or regulation. None of the Company or any member of its Aggregated Group has caused any of its employees to suffer an "employment loss" (as defined in the WARN Act) during the ninety (90) day period prior to the date hereof, nor shall do so before the Closing Date.

(s) **Intellectual Property.**

(i) Company Disclosure Schedule 3.1(s)(i) sets forth a complete and accurate list of all Registered IP owned by the Company or its Subsidiaries and all license agreements conferring Intellectual Property Rights to the Company or its Subsidiaries and such Company Disclosure Schedule 3.1(s)(i) indicates for each item of such Intellectual Property whether such Intellectual Property is owned (whether solely or jointly with others) or licensed by the Company or such Subsidiary.

(ii) The Company and its Subsidiaries own (and immediately after Closing (including immediately after the consummation of the Divestiture), the Surviving Corporation will own, subject to the express provisions of the Contracts set forth in Sections 2.11(b) – (g) of the Asset Purchase Agreement and assuming no action that changes such ownership is taken by Surviving Corporation beyond performance under this Agreement, including consummation of the transactions contemplated hereunder), free and clear of any Liens, all right, title and interest in and to the Company IP (other than Company IP that is licensed to the Company) and all other Intellectual Property and Intellectual Property Rights indicated on Company Disclosure Schedule 3.1(s)(i) as being owned by the Company. Company Disclosure Schedule 3.1(s)(i) identifies each option, license or Contract of any kind relating to Intellectual Property that, (i) individually, resulted in payments to or from the Company during the fiscal year ended December 31, 2004 in an amount greater than \$150,000 or that, during the current fiscal year, is reasonably expected by the Company to involve payments to or from the Company equal to or greater than \$150,000 or (ii) if lost, impaired or terminated, would reasonably be expected to have a Material Adverse Effect on the business, properties or financial condition of the Company and its Subsidiaries taken as a whole (including, without limitation, assignment agreements, in and out-licenses but

IN WITNESS WHEREOF, the Company, Parent, Merger Subsidiary and the Representative have caused this Agreement to be signed, all as of the date first written above.

THE COMPANY:

AMBION, INC.

By: _____
Name: _____
Title: _____

PARENT:

APPLERA CORPORATION

By: Catherine M. Burzik
Name: Catherine M. Burzik
Title: President, Applied Biosystems Group

MERGER SUBSIDIARY:

AMBION ACQUISITION CORP.

By: Catherine M. Burzik
Name: Catherine M. Burzik
Title: Vice President


MATTHEW M. WINKLER,
solely in his capacity as the Representative

AMBION, INC.
AGREEMENT AND PLAN OF MERGER

IN WITNESS WHEREOF, the Company, Parent, Merger Subsidiary and the Representative have caused this Agreement to be signed, all as of the date first written above.

THE COMPANY:

AMBION, INC.

By: 
Name: Matthew Winkler
Title: CEO

PARENT:

APPLERA CORPORATION

By: _____
Name: _____
Title: _____

MERGER SUBSIDIARY:

AMBION ACQUISITION CORP.

By: _____
Name: _____
Title: _____

MATTHEW M. WINKLER,
solely in his capacity as the Representative



SIGNATURE PAGE TO
AMBION, INC.
AGREEMENT AND PLAN OF MERGER

Schedule 3.1(s)(i)

Registered Intellectual Property Owned by the Company or Its Subsidiary

1. Wholly owned patents are listed in Appendix A, which is incorporated herein by reference.
2. Jointly owned patents are listed in Appendix B, which is incorporated herein by reference.
3. Company owned registered copyrights are listed in Appendix C, which is incorporated herein by reference.
4. Company owned registered trademarks are listed in Appendix D, which is incorporated herein by reference.

License Agreements Conferring Intellectual Property Rights to the Company or Its Subsidiary

1. License agreements listed in Schedule 3.1(q) of this Agreement and Plan of Merger and Appendix E, which are incorporated herein by reference.

Contracts Related to Intellectual Property

1. All Material Contracts listed in Schedule 3.1(q) of this Agreement and Plan of Merger and all contracts and agreements listed in Appendix E, which are incorporated herein by reference.

APPENDIX A to Schedule 3.1(s)

LIST OF ISSUED, PENDING AND ABANDONED AMBION APPLICATIONS				
Application No.	Serial No.	Registration No.	Title	Case Status (external)
07/724,423		5,422,241	METHODS & COMPOSITIONS FOR THE RECOVERY OF NUCLEIC ACIDS FROM REACTION MIXTURES	Issued
			A NUCLEASE PROTECTION METHOD FOR DETECTING & QUANTITATING AMOUNTS OF SPECIFIC NUCLEIC ACIDS	Abandoned
07/810,968		5,256,555	COMPOSITIONS AND METHODS FOR INCREASING THE YIELDS OF IN VITRO RNA TRANSCRIPTION AND OTHER POLYNUCLEOTIDE SYNTHETIC REACTIONS	Issued
US92/10931			COMPOSITIONS AND METHODS FOR INCREASING THE YIELDS OF IN VITRO RNA TRANSCRIPTION AND OTHER POLYNUCLEOTIDE SYNTHETIC REACTIONS	Abandoned
08/108,115			COMPOSITION AND METHODS FOR INCREASING YIELDS OF IN-VITRO RNA TRANSCRIPTION *	Abandoned
08/323,602			COMPOSITION AND METHODS FOR INCREASING YIELDS OF IN-VITRO RNA TRANSCRIPTION *	Abandoned
09/966,062		6,586,218	COMPOSITIONS AND METHODS FOR INCREASING THE YIELDS OF IN VITRO RNA TRANSCRIPTION AND OTHER POLYNUCLEOTIDE SYNTHETIC REACTIONS	Issued
09/966,494		6,586,219	COMPOSITIONS AND METHODS FOR INCREASING THE YIELDS OF IN VITRO RNA TRANSCRIPTION AND OTHER POLYNUCLEOTIDE SYNTHETIC REACTIONS	Issued
10/442,591			COMPOSITIONS AND METHODS FOR INCREASING THE YIELDS OF IN VITRO RNA TRANSCRIPTION AND OTHER POLYNUCLEOTIDE SYNTHETIC REACTIONS	Abandoned
08/155,937		5,589,329	IMPROVED METHODS AND COMPOSITIONS FOR BASE PAIR MISMATCHES	Issued
08/099,867		5,547,862	VECTORS CONTAINING MULTIPLE PROMOTERS IN THE SAME ORIENTATION	Issued

LIST OF ISSUED, PENDING AND ABANDONED AMBION APPLICATIONS

Application No.	Serial No.	Registration No.	Title	Case Status (external)
08/371,531			METHODS AND COMPOSITIONS FOR DETECTING BASE PAIR MISMATCHES IN DOUBLE STRANDED RNA	Abandoned
08/408,596			HIGH SPEED NUCLEIC ACID HYBRIDIZATION UTILIZING CATIONIC DETERGENTS IN THE PRESENCE OF NON-CATIONIC DETERGENTS - IMPROVEMENT ON TECHNOLOGY LICENSED FROM STANFORD UNIVERSITY	Abandoned
08/742,561			FWC - HIGH SPEED NUCLEIC ACID HYBRIDIZATION UTILIZING CATIONIC DETERGENTS IN THE PRESENCE OF NON-CATIONIC DETERGENTS - IMPROVEMENT ON TECHNOLOGY LICENSED FROM STANFORD UNIVERSITY	Abandoned
08/503,222			DETECTION OF NUCLEASES	Abandoned
08/534,977		5,891,629	COMPOSITIONS FOR IMPROVING RNASE CLEAVAGE OF ASE PAIR MISMATCHES IN DOUBLE STRANDED NUCLEIC ACIDS	Issued
US96/00073			METHODS AND COMPOSITIONS FOR USE IN CLEAVAGE AND DETECTION OF BASE MISMATCHES IN DOUBLE STRANDED NUCLEIC ACIDS	Abandoned
08/675,153		5,677,124	RIBONUCLEASE RESISTANT VIRAL RNA STANDARDS	Issued
08/841,252		5,919,625	RIBONUCLEASE RESISTANT VIRAL RNA STANDARDS	Issued
60/021,145			METHOD FOR LARGE SCALE RNA SYNTHESIS AND PURIFICATION	Expired
278440		278440	AMBION	Registered
08/726,519		6,057,134	MODULATING THE EFFICIENCY OF NUCLEIC ACID AMPLIFICATION REACTIONS WITH 3' MODIFIED OLIGONUCLEOTIDES	Issued
08/881,571		5,939,262	RIBONUCLEASE RESISTANT RNA PREPARATION AND UTILIZATION	Issued

LIST OF ISSUED, PENDING AND ABANDONED AMBION APPLICATIONS				
Application No.	Serial No.	Registration No.	Title	Case Status (external)
09/665,638		6,399,307	METHODS OF QUANTIFYING VIRAL LOAD IN AN ANIMAL WITH A RIBONUCLEASE RESISTANT RNA PREPARATION (AS AMENDED)	Issued
10/120,013			RIBONUCLEASE RESISTANT RNA PREPARATION AND UTILIZATION	Allowed
08/908,536			NUCLEIC ACID DEGRADING SOLUTION	Abandoned
08/906,038			METHODS AND COMPOSITIONS FOR	Abandoned
08/907,195		6,365,731	STRIPPING NUCLEIC ACIDS WITH IODINE AND SODIUM THIOSULFATE	Issued
98938321.1			METHODS AND COMPOSITIONS FOR STRIPPING NUCLEIC ACIDS	Abandoned
US98/16183			METHODS AND COMPOSITIONS FOR STRIPPING NUCLEIC ACIDS	Entered National Phase
		6,891,032	METHODS AND COMPOSITIONS FOR STRIPPING NUCLEIC ACIDS	Issued
36709/97		729601	RIBONUCLEASE RESISTANT RNA PREPARATION AND UTILIZATION	Issued
2,258,485			RIBONUCLEASE RESISTANT RNA PREPARATION AND UTILIZATION	Pending
97933547.8			RIBONUCLEASE RESISTANT RNA PREPARATION AND UTILIZATION	Pending
			RIBONUCLEASE RESISTANT RNA PREPARATION AND UTILIZATION	Pending
US97/12551			RIBONUCLEASE RESISTANT RNA PREPARATION AND UTILIZATION - CIP	Entered National Phase
09/048,365			HIGH SPEED NUCLEIC ACID HYBRIDIZATION UTILIZING CATIONIC DETERGENTS IN THE PRESENCE OF NON CATIONIC DETERGENTS - DIVISIONAL	Abandoned
09/127,435		6,204,375	METHODS AND REAGENTS FOR PRESERVING RNA IN CELL AND TISSUE SAMPLES	Issued
09/160,284		6,777,210	METHOD AND REAGENTS FOR INACTIVATING RIBONUCLEASES RNASE A, RNASE I AND RNASE T1	Issued

LIST OF ISSUED, PENDING AND ABANDONED AMBION APPLICATIONS

Application No.	Serial No.	Registration No.	Title	Case Status (external)
54616/99		745943	METHODS AND REAGENTS FOR PRESERVING RNA IN CELL AND TISSUE SAMPLES - CIP	Issued
2,298,841			METHODS AND REAGENTS FOR PRESERVING RNA IN CELL AND TISSUE SAMPLES - CIP	Pending
99940837			METHODS AND REAGENTS FOR PRESERVING RNA IN CELL AND TISSUE SAMPLES - CIP	Pending
99940837			METHODS AND REAGENTS FOR PRESERVING RNA IN CELL AND TISSUE SAMPLES - CIP	Issued
99940837			METHODS AND REAGENTS FOR PRESERVING RNA IN CELL AND TISSUE SAMPLES - CIP	Issued
99940837			METHODS AND REAGENTS FOR PRESERVING RNA IN CELL AND TISSUE SAMPLES - CIP	Issued
99940837			METHODS AND REAGENTS FOR PRESERVING RNA IN CELL AND TISSUE SAMPLES - CIP	Issued
99940837			METHODS AND REAGENTS FOR PRESERVING RNA IN CELL AND TISSUE SAMPLES - CIP	Issued
99940837			METHODS AND REAGENTS FOR PRESERVING RNA IN CELL AND TISSUE SAMPLES - CIP	Issued
99940837			METHODS AND REAGENTS FOR PRESERVING RNA IN CELL AND TISSUE SAMPLES - CIP	Issued
99940837			METHODS AND REAGENTS FOR PRESERVING RNA IN CELL AND TISSUE SAMPLES - CIP	Issued
99940837			METHODS AND REAGENTS FOR PRESERVING RNA IN CELL AND TISSUE SAMPLES - CIP	Issued
99940837			METHODS AND REAGENTS FOR PRESERVING RNA IN CELL AND TISSUE SAMPLES - CIP	Issued
99940837			METHODS AND REAGENTS FOR PRESERVING RNA IN CELL AND TISSUE SAMPLES - CIP	Issued

LIST OF ISSUED, PENDING AND ABANDONED AMBION APPLICATIONS				
Application No.	Serial No.	Registration No.	Title	Case Status (external)
99940837			METHODS AND REAGENTS FOR PRESERVING RNA IN CELL AND TISSUE SAMPLES - CIP	Issued
99940837			METHODS AND REAGENTS FOR PRESERVING RNA IN CELL AND TISSUE SAMPLES - CIP	Issued
562562/2000			METHODS AND REAGENTS FOR PRESERVING RNA IN CELL AND TISSUE SAMPLES - CIP	Pending
US99/17375			METHODS AND REAGENTS FOR PRESERVING RNA IN CELL AND TISSUE SAMPLES - CIP	Entered National Phase
09/771,256		6,528,641	METHODS AND REAGENTS FOR PRESERVING RNA IN CELL AND TISSUE S AMPLES	Issued
10/354,727			METHODS AND REAGENTS FOR PRESERVING RNA IN CELL AND TISSUE S AMPLES	Pending
966924.3			NUCLEASE INHIBITOR COCKTAIL	Pending
60/155,874			MIXTURES OF ANTI-RNASE COCKTAIL FOR THE INACTIVATION OF RIBONUCLEASES	Expired
09/669,301		6,664,379	NUCLEASE INHIBITOR COCKTAIL	Issued
10/675,860			NUCLEASE INHIBITOR COCKTAIL	Pending
US00/26485			NUCLEASE INHIBITOR COCKTAIL	Entered National Phase
2,360,539			METHODS AND REAGENTS FOR INACTIVATING RIBONUCLEASES - CIP	Abandoned
99948453.8			METHODS AND REAGENTS FOR INACTIVATING RIBONUCLEASES - CIP	Abandoned
US99/22230			METHODS AND REAGENTS FOR INACTIVATING RIBONUCLEASES - CIP	Entered National Phase
09/815,577		6,825,340	METHODS AND REAGENTS FOR INACTIVATING RIBONUCLEASES	Issued
09/618,535			METHOD FOR RECOMBINATORIAL NUCLEIC ACID SYNTHESIS	Allowed
US01/22195			METHOD FOR RECOMBINATORIAL NUCLEIC ACID SYNTHESIS	Abandoned

LIST OF ISSUED, PENDING AND ABANDONED AMBION APPLICATIONS				
Application No.	Serial No.	Registration No.	Title	Case Status (external)
60/265,693			METHODS FOR NUCLEIC ACID FINGERPRINT ANALYSIS	Expired
US02/03168			METHODS FOR NUCLEIC ACID FINGERPRINT ANALYSIS	Abandoned
2720894.1			COMPARATIVE ANALYSIS OF NUCLEIC ACIDS USING POPULATION TAGGING	Published
10/632,539			COMPARATIVE ANALYSIS OF NUCLEIC ACIDS USING POPULATION TAGGING	Pending
60/265,694			COMPARATIVE ANALYSIS OF NUCLEIC ACIDS USING POPULATION TAGGING	Expired
US02/03097			COMPARATIVE ANALYSIS OF NUCLEIC ACIDS USING POPULATION TAGGING	Entered National Phase
60/265,695			COMPETITIVE POPULATION NORMALIZATION FOR COMPARATIVE ANALYSIS OF NUCLEIC ACID SAMPLES	Expired
US02/02892			COMPETITIVE POPULATION NORMALIZATION FOR COMPARATIVE ANALYSIS OF NUCLEIC ACID SAMPLES	Abandoned
10/632,534			COMPETITIVE AMPLIFICATION OF FRACTIONATED TARGETS FROM MULTIPLE NUCLEIC ACID SAMPLES	Published
60/265,692			COMPETITIVE AMPLIFICATION OF FRACTIONATED TARGETS FROM MULTIPLE NUCLEIC ACID SAMPLES	Expired
US02/03169			COMPETITIVE AMPLIFICATION OF FRACTIONATED TARGETS FROM MULTIPLE NUCLEIC ACID SAMPLES	Abandoned
		GB2378445	HIGH EFFICIENCY mRNA ISOLATION	Issued
		6,812,341	HIGH EFFICIENCY mRNA ISOLATION METHODS AND COMPOSITIONS	Issued
2002359789			METHOD AND SYSTEM FOR DEPLETING rRNA POPULATIONS	Abandoned
2,468,854			METHOD AND SYSTEM FOR DEPLETING rRNA POPULATIONS	Abandoned

LIST OF ISSUED, PENDING AND ABANDONED AMBION APPLICATIONS				
Application No.	Serial No.	Registration No.	Title	Case Status (external)
2794350.5			METHOD AND SYSTEM FOR DEPLETING rRNA POPULATIONS	Abandoned
10/029,397			METHOD AND SYSTEM FOR DEPLETING rRNA POPULATIONS	Abandoned
US02/41014			METHOD AND SYSTEM FOR DEPLETING rRNA POPULATIONS	Entered National Phase
2003212886			HIGH POTENCY SIRNAS FOR REDUCING THE EXPRESSION OF TARGET GENES	Abandoned
3708928.1			HIGH POTENCY SIRNAS FOR REDUCING THE EXPRESSION OF TARGET GENES	Application Filed
10/355,820			HIGH POTENCY SIRNAS FOR REDUCING THE EXPRESSION OF TARGET GENES	Published
60/353,332			HIGH POTENCY SIRNAS FOR REDUCING THE EXPRESSION OF TARGET GENES	Expired
PCT/US2003/03023			A HIGH POTENCY SIRNAS FOR REDUCING THE EXPRESSION OF TARGET GENES	Entered National Phase
2003214916			CRUDE BIOLOGICAL DERIVATIVES COMPETENT FOR NUCLEIC ACID DETECTION	Abandoned
3710760.4			CRUDE BIOLOGICAL DERIVATIVES COMPETENT FOR NUCLEIC ACID DETECTION	Application Filed
10/352,806			CRUDE BIOLOGICAL DERIVATIVES COMPETENT FOR NUCLEIC ACID DETECTION	Published
60/352,402			CRUDE BIOLOGICAL DERIVATIVES COMPETENT FOR NUCLEIC ACID DETECTION	Expired
PCT/US2003/02439			CRUDE BIOLOGICAL DERIVATIVES COMPETENT FOR NUCLEIC ACID DETECTION	Entered National Phase
500265.4			METHODS AND COMPOSITIONS RELATING TO LABELED RNA MOLECULES THAT REDUCE GENE EXPRESSION	Pending

LIST OF ISSUED, PENDING AND ABANDONED AMBION APPLICATIONS				
Application No.	Serial No.	Registration No.	Title	Case Status (external)
10/360,772			METHODS AND COMPOSITIONS RELATING TO LABELED RNA MOLECULES THAT REDUCE GENE EXPRESSION	Published
60/388,547			METHODS AND COMPOSITIONS RELATING TO LABELED RNA MOLECULES THAT REDUCE GENE EXPRESSION	Expired
PCT/US2003/18627			METHODS AND COMPOSITIONS RELATING TO LABELED RNA MOLECULES THAT REDUCE GENE EXPRESSION	Entered National Phase
3741956.1			METHODS AND COMPOSITIONS RELATING TO POLYPEPTIDES WITH RNASE III DOMAINS THAT MEDIATE RNA INTERFERENCE	Application Filed
10/460,775			METHODS AND COMPOSITIONS RELATING TO POLYPEPTIDES WITH RNASE III DOMAINS THAT MEDIATE RNA INTERFERENCE	Published
60/402,347			METHODS AND COMPOSITIONS RELATING TO POLYPEPTIDES WITH RNASE III DOMAINS THAT MEDIATE RNA INTERFERENCE	Expired
PCT/US2003/018626			METHODS AND COMPOSITIONS RELATING TO POLYPEPTIDES WITH RNASE III DOMAINS THAT MEDIATE RNA INTERFERENCE	Entered National Phase
10/298,480			METHODS AND COMPOSITIONS FOR REDUCING TARGET GENE EXPRESSION USING COCKTAILS OF SIRNAS OR CONSTRUCTS EXPRESSING SIRNAS	Published
PCT/US2003/036401			METHODS AND COMPOSITIONS FOR REDUCING TARGET GENE EXPRESSION USING COCKTAILS OF SIRNAS OR CONSTRUCTS EXPRESSING SIRNAS	Abandoned
516075.9			COMPOSITIONS AND METHODS FOR PRESERVING RNA IN BIOLOGICAL SAMPLES	Application Filed
10/360,784			COMPOSITIONS AND METHODS FOR PRESERVING RNA IN BIOLOGICAL SAMPLES	Application Filed

LIST OF ISSUED, PENDING AND ABANDONED AMBION APPLICATIONS				
Application No.	Serial No.	Registration No.	Title	Case Status (external)
PCT/US2004/003012			COMPOSITIONS AND METHODS FOR PRESERVING RNA IN BIOLOGICAL SAMPLES	Entered National Phase
10/462,091			METHOD OF COMPOSITIONS FOR PREPARING TISSUE SAMPLES FOR RNA EXTRACTION	Published
PCT/US2004/018597			METHODS AND COMPOSITIONS FOR PREPARING TISSUE SAMPLES FOR RNA EXTRACTION	Published
10/667,126			METHODS AND COMPOSITIONS FOR ISOLATING SMALL RNA MOLECULES	Published
PCT/US2004/023850			METHODS AND COMPOSITIONS FOR ISOLATING SMALL RNA MOLECULE	Published
10/899,386			METHODS AND COMPOSITIONS FOR PREPARING RNA FROM A FIXED SAMPLE	Published
60/490,325			METHOD AND COMPOSITIONS FOR PREPARING RNA FROM A FIXED SAMPLE	Expired
PCT/US2004/024155			METHODS AND COMPOSITIONS FOR PREPARING RNA FROM A FIXED SAMPLE	Published
10/786,875			IMPROVED NUCLEASE INHIBITOR COCKTAIL	Published
PCT/US2005/006394			IMPROVED NUCLEASE INHIBITOR COCKTAIL	Published
60/514,313			BIOLOGICAL SAMPLE DISRUPTION TECHNIQUES	Expired
PCT/US2004/034850			BIOLOGICAL SAMPLE DISRUPTION TECHNIQUES	Application Filed
10/880,350			METHODS AND COMPOSITIONS FOR PREPARING CAPPED RNA	Application Filed
PCT/US2005/22710			METHODS AND COMPOSITIONS FOR PREPARING CAPPED RNA	Application Filed
10/935,534			METHODS AND COMPOSITIONS FOR POLYADENYLATION OF mRNA	Application Filed
PCT/US2005/032227			METHODS AND COMPOSITIONS FOR TAILING AND AMPLIFYING RNA	Application Filed
10/801,982			PROCESS AND REAGENTS FOR EXTRACTION OF RNA FROM FRACTIONATED BLOOD LEUKOCYTES	Published

LIST OF ISSUED, PENDING AND ABANDONED AMBION APPLICATIONS				
Application No.	Serial No.	Registration No.	Title	Case Status (external)
PCT/US2005/008826			PROCESS AND REAGENTS FOR EXTRACTION OF RNA FROM FRACTIONATED BLOOD LEUKOCYTES	Published
60/547,721			NUCLEASE INHIBITORS FOR USE IN BIOLOGICAL APPLICATIONS	Expired
11/141,707			METHODS AND COMPOSITIONS INVOLVING MICRORNA	Pending
60/575,743			METHODS AND COMPOSITIONS INVOLVING MICRORNA	Expired
60/649,584			METHODS AND COMPOSITIONS INVOLVING MICRORNA	Expired
PCT/US2005/018826			METHODS AND COMPOSITIONS INVOLVING MICRORNA	Pending
10/955,974			MODIFIED SURFACES AS SOLID SUPPORTS FOR NUCLEIC ACID PURIFICATION	Published
60/554,278			DEXTRAN-MODIFIED SURFACES AS SOLID SUPPORTS FOR NUCLEIC ACID PURIFICATION	Expired
PCT/US05/09189			MODIFIED SURFACES AS SOLID SUPPORTS FOR NUCLEIC ACID PURIFICATION	Published
10/866,525			CRUDE BIOLOGICAL DERIVATIVES COMPETENT FOR NUCLEIC ACID DETECTION	Application Filed
PCT/US2005/20602			CRUDE BIOLOGICAL DERIVATIVES COMPETENT FOR NUCLEIC ACID DETECTION	Application Filed
10/963,415			METHODS AND COMPOSITIONS FOR ANALYZING NUCLEIC ACIDS	Application Filed
PCT/US05/36799			METHODS AND COMPOSITIONS FOR ANALYZING NUCLEIC ACIDS	Application Filed
60/615,248			NON-EMBEDDED TISSUE MICROARRAY TECHNOLOGY FOR PROTEIN AND NUCLEIC ACID ANALYSES	Expired
PCT/US05/35001			NON-EMBEDDED TISSUE MICROARRAY TECHNOLOGY FOR PROTEIN AND NUCLEIC ACID ANALYSES	Application Filed

LIST OF ISSUED, PENDING AND ABANDONED AMBION APPLICATIONS				
Application No.	Serial No.	Registration No.	Title	Case Status (external)
60/685,453			METHODS AND COMPOSITIONS FOR DEPLETING ABUNDANT RNA TRANSCRIPTS	Application Filed
11/273,640			METHODS AND COMPOSITIONS INVOLVING MODIFIED MIRNA MOLECULES AND MIRRNA INHIBITOR MOLECULES	Application Filed
60/627,171			METHODS AND COMPOSITIONS INVOLVING MODIFIED MIRNA MOLECULES AND MIRRNA INHIBITOR MOLECULES	Expired
60/649,634			METHODS AND COMPOSITIONS INVOLVING MODIFIED mirRNA MOLECULES AND mirRNA INHIBITOR MOLECULES	Application Filed
60/683,736			METHODS AND COMPOSITIONS INVOLVING MODIFIED mirRNA MOLECULES AND mirRNA INHIBITOR MOLECULES	Application Filed
PCT/US2005/41162			METHODS AND COMPOSITIONS INVOLVING MODIFIED MIRNA MOLECULES AND MIRRNA INHIBITOR MOLECULES	Application Filed
11/020,560			METHODS AND COMPOSITIONS CONCERNING SIRNA'S AS MEDIATORS OF RNA INTERFERENCE	Application Filed
Not assigned			METHODS AND COMPOSITIONS CONCERNING SIRNA'S AS MEDIATORS OF RNA INTERFERENCE	Application Filed
11/076,455			ENZYMATIC DIGESTION OF TISSUE	Application Filed
60/654,219			ENZYMATIC DIGESTION OF TISSUE	Application Filed
Not assigned			REVERSE TRANSCRIPTION PRIMERS AND METHODS OF DESIGN	Application Filed
60/732,770			METHOD OF DETECTING DIFFERENTIALLY EXPRESSED GENES THROUGH PROBE LEVEL DATA FROM OLIGONUCLEOTIDE ARRAYS	Application Filed
	10/420,345		Compositions and Methods of Using a Synthetic DNase I	Allowed

LIST OF ISSUED, PENDING AND ABANDONED AMBION APPLICATIONS				
Application No.	Serial No.	Registration No.	Title	Case Status (external)
	10/404,023		Compositions and Methods of Using a Synthetic Bovine DNase I	Abandoned
	10/827,498		Recombinant Reverse Transcriptases	Pending
			rRNase Production Patent	Not Filed Yet
			Simultaneous Detection of Leukemia-Associated Chromosome Translocations	Pending
	PCT/US2004/009955		Compositions and Methods of Using a Synthetic DNase I	Done
	PCT/US2005/012671		Recombinant Reverse Transcriptases	Pending
	04749602.1		Compositions and Methods of Using a Synthetic DNase I	Pending
10/883186			System and Method for Processing Results of a Complex Genetic Test	Pending
10/863102		US6897069B1	System and Method for Electroporating a Sample	Granted
11/130884			System and Method for Electroplating a Sample	Pending
US05/18058			System and Method for Electroporating a Sample	Pending
US05/23348			System and Method for Processing Results of a Complex Genetic Test	Pending
60/736438			Compositions, Methods, Devices, and Systems for Nucleic Acid Fractionation	Pending